Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 4Liver Neoplasms 2Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Liver Diseases 1Hepatitis 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrosis 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Sorafenib 131lenvatinib 115Bevacizumab 88Radiosurgery 69atezolizumab 55sintilimab 54Nivolumab 51durvalumab 43Hepatectomy 43Fluorouracil 42apatinib 41Oxaliplatin 41camrelizumab 38Radiofrequency Ablation 38pembrolizumab 36Radiotherapy 36tislelizumab 35Leucovorin 31Magnetic Resonance Spectroscopy 30Immune Checkpoint Inhibitors 28Doxorubicin 28Folfox protocol 26tremelimumab 25regorafenib 25Cisplatin 20spartalizumab 19donafenib 19Gemcitabine 19Cyclophosphamide 19toripalimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Hepatocellular × bavituximab × Clear all
NCT03519997 2026-02-11

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

University of Texas Southwestern Medical Center

Phase 2 Active not recruiting
35 enrolled 10 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT05249569 2023-05-03

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

University of Texas Southwestern Medical Center

Phase 2 Terminated
1 enrolled 4 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01264705 2020-11-12

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

University of Texas Southwestern Medical Center

Phase 1/2 Completed
47 enrolled 10 charts
Gastrointestinal

Fibrosis, Gastrointestinal Neoplasms, Hepatitis, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡